QQQ $ 443.93 $ -0.82 (-0.18 %)
DIA $ 397.72 $ 0.20 (0.05 %)
SPY $ 523.07 $ -0.10 (-0.02 %)
TLT $ 94.55 $ -0.08 (-0.08 %)
GLD $ 205.72 $ 2.62 (1.29 %)
$ 0.0905
-- x --
-- x --
-- - --
$ 0.04 - $ 0.36
11,000
na
na
$ 0.71
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 psychedelics-headlines-anti-inflammatory-effects-global-drug-survey-synthetic-surprise-uks-harm-reduction-hub-and-more

Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and onli...

 psyched-biden-approves-psychedelics-trials-rfk-australias-first-legal-dedicated-clinic--more

President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 Nat...

 awakn-life-sciences-enters-into-global-licensing-agreement-for-sublingual-delivery-formulation

Awakn Life Sciences (OTC: AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted t...

 psyched-ramaswamy-psychedelics-for-ptsd-uk-clinical-trials-johns-hopkins-qa-and-more

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan

 uk-psychedelics-phase-3-depression--alcohol-addiction-trials-new-london-center

The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass P...

 uks-prof-david-nutt-ranked-worlds-top-psychopharmacologist-more-on-his-contributions--advocacy

Professor David Nutt, a cognitive sciences, addiction, cannabis and psychedelics researcher, has been ranked the #1 psychopharm...

 psyched-psilocybin-therapy-for-depression-uk-rescheduling-us-policy-reform-and-more

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For...

 awakn-life-sciences-submits-cta-for-phase-iii-alcohol-use-disorder-clinical-trial

Awakn Life Sciences Corp. (OTC: AWKNF), a biotech firm focused on developing therapies for addiction, with a primary emphasis o...

 psyched-professional-practice-guidelines-dmt-for-stroke-dua-lipa--amanda-feilding-clinical-results--more

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

 psyched-portugal-decriminalizes-synthetic-drugs-anorexia-and-psilocybin-lsd-microdosing-california--more

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of syn...

 awakn-life-sciences-becomes-pure-rd-biotech-after-sale-of-norway-clinics

As part of its business restructuring process and following its London clinics busin

 awakn-life-sciences-on-track-with-phase-3-trial-to-research-substance-use-disorder

On this new Psychedelics Exclusive podcast, TDR Founder Shadd Dales interviews Awakn Life Sciences Corp. (OTC: AWKNF) CEO Antho...

 psyched-australias-innovative-program-congressional-amendments-therapy-reimbursement-and-more

First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became ...

 awakn-life-sciences-sells-london-clinics-business-hopes-to-divest-norwegian-unit-next

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) sold its London subsidiary and healthcare clinic.

 psyched-75m-in-federal-funds-gov-polis-opens-maps-event-cnns-show-dock-ellis-lsd-pitch--more

Federal Psychedelics: $75M Grant Program

 psyched-75m-in-federal-funds-gov-polis-opens-maps-event-cnns-show-dock-ellis-lsd-pitch--more

Federal Psychedelics: $75M Grant Program

 awakn-life-sciences-announces-closing-of-second-tranche-and-upsizing-of-previous-private-placement

UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) announced the closing of the second tranche of its lates...

 awakn-to-focus-on-rd-of-addiction-therapies-moves-away-from-ketamine-treatment-for-alcoholism

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) is set to exit ketamine healthcare services to focus solely on re...

 psyched-oregon-and-colorado-regulations-mindmed-ceo-discusses-lsd-therapy-mia-khalifa-enters-market--more

Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION